Improvement of the synthesis and pharmacokinetic properties of chromenotriazolopyrimidine MDM2-p53 protein-protein inhibitors

Bioorg Med Chem Lett. 2011 May 1;21(9):2752-5. doi: 10.1016/j.bmcl.2010.11.027. Epub 2010 Nov 10.

Abstract

Human murine double minute 2 (MDM2) is a negative regulator of p53, which plays an important role in cell cycle and apoptosis. We report several optimizations to the synthesis of the chromenotriazolopyrimidine series of MDM2-p53 protein-protein interaction inhibitors. Additionally, the in vitro and in vivo stability, pharmacokinetic properties and solubility were improved through N-substitution.

MeSH terms

  • Animals
  • Drug Stability
  • Humans
  • Infusion Pumps
  • Inhibitory Concentration 50
  • Molecular Structure
  • Proto-Oncogene Proteins c-mdm2 / antagonists & inhibitors*
  • Pyrimidines / chemical synthesis*
  • Pyrimidines / pharmacokinetics
  • Rats
  • Solubility
  • Structure-Activity Relationship
  • Tumor Suppressor Protein p53 / antagonists & inhibitors*

Substances

  • Pyrimidines
  • Tumor Suppressor Protein p53
  • Proto-Oncogene Proteins c-mdm2